Back

Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE–TIMI 58 for the basic science community

Cardiovascular Research

24 April 2019
Organised by: Logo
Read full article
ESC Journals

Contributors

Hidekazu Kondo
Hidekazu Kondo

Author

Naohiko Takahashi
Naohiko Takahashi

Author

Oita University Faculty of Medicine Oita , Japan

You may be interested in
thumbnail
Congress Session
Diabetes, obesity, and heart failure
19 May 2025
thumbnail
Congress Presentation
Effects of dapagliflozin on hospitalizations for heart failure according to severity of inpatient treatment course: the DELIVER Trial
21 May 2023
thumbnail
Congress Session
Late-breaking science in acute heart failure
19 May 2025
thumbnail
Congress Session
Young Investigator Award (YIA) Basic Science
17 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources